Bashas’ to offer a Senior Discount Day
CHANDLER, Ariz. A grocery store chain that recently filed for bankruptcy protection hopes to lure more customers with a discount program.
Bashas’ announced that it would offer a Senior Discount Day, offering a 10% discount to customers 55 years and older who purchase more than $15 worth of goods. The discount would not cover alcohol, tobacco or prescription drugs.
Bashas’ filed for bankruptcy protection under Chapter 11 last month, closing 10 stores in Arizona on July 21.
Wireless home-based healthcare applications, services set to grow, analysis finds
DALLAS The U.S. market for wireless home-based healthcare applications and services will grow at a five-year cumulative annual growth rate of more than 180% and become a $4.4 billion industry by 2013, according to Parks Associates’ “Wireless Healthcare: Analysis & Forecasts” report released Aug. 5.
Parks predicts the push for healthcare reform from the Obama administration will ultimately boost adoption of wireless technologies in healthcare. The federal government is committed to promoting technology that improves healthcare efficiency, evident in the stimulus funds already allocated to electronic medical records adoption, and this focus will open new long-term opportunities for wireless providers, Parks executives predict.
“Wireless is an important crossover point for the healthcare sector and high-tech industry,” stated Harry Wang, director, Health & Mobile Product Research, Parks Associates. “Device and service connectivity is the model for future home care applications, and mobile networks will link a growing number of monitoring products to healthcare providers.”
The report suggests that mobile carriers will leverage their network resources to target vertical markets like healthcare through both wholesale and retail partnerships. Deals such as recent agreements from Verizon Wireless with LifeWatch and Qualcomm will become more commonplace as this market moves into wider availability.
AdventRx submits approval application for chemotherapy drug
SAN DIEGO A drug maker in Southern California plans to submit an approval application for a new chemotherapy drug by the end of the year.
AdventRx Pharmaceuticals announced Tuesday that it would submit a new drug application to the Food and Drug Administration for its chemotherapy emulsion ANX-530 (vinorelbine).
“Our recently completed manufacturing activities represented the last major hurdle before our NDA submission,” AdventRx principal executive officer Brian Culley said in a statement. “While we continue to evaluate the bioequivalence and preclinical data, we have begun the substantial process of compiling the information required for a submission, which we expect to take place by the end of this year.”